Cargando…

Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease

Prostate cancer (PCa) is a major diagnosed cancer among men globally, and about 20% of patients develop metastatic prostate cancer (mPCa) in the initial diagnosis. PCa is a typical androgen-dependent disease; thus, hormonal therapy is commonly used as a standard care for mPCa by inhibiting androgen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bo-Ren, Chen, Yu-An, Kao, Wei-Hsiang, Lai, Chih-Ho, Lin, Ho, Hsieh, Jer-Tsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405166/ https://www.ncbi.nlm.nih.gov/pubmed/36009418 http://dx.doi.org/10.3390/biomedicines10081872

Ejemplares similares

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
por: Liu, Hsin-Ho, et al.
Publicado: (2014)

The driver role of JAK‐STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy‐ and castration‐resistant prostate cancer
por: Lo, U‐Ging, et al.
Publicado: (2022)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Naseer, Faiza, et al.
Publicado: (2021)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)

Sensitization of Radioresistant Prostate Cancer Cells by Resveratrol Isolated from Arachis hypogaea Stems
por: Chen, Yu-An, et al.
Publicado: (2017)

The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC
por: Lee, Cheng‐Fan, et al.
Publicado: (2022)

Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
por: Zaborowska, Magdalena, et al.
Publicado: (2012)

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways
por: Chen, Yu-An, et al.
Publicado: (2018)

Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin
por: Lai, Chih-Ho, et al.
Publicado: (2014)

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2021)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
por: Acar, Ömer, et al.
Publicado: (2013)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

New ideas in preventing castration-resistant prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2017)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

Development and prevalence of castration-resistant prostate cancer subtypes
por: Vellky, Jordan E., et al.
Publicado: (2020)

Cytolethal Distending Toxin Enhances Radiosensitivity in Prostate Cancer Cells by Regulating Autophagy
por: Lin, Hwai-Jeng, et al.
Publicado: (2017)

The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes
por: Yun, Eun-Jin, et al.
Publicado: (2017)

Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer
por: Ojo, Diane, et al.
Publicado: (2015)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

The role of microRNAs in prostate cancer progression
por: Lo, U-Ging, et al.
Publicado: (2013)

The regulatory pathways leading to stem-like cells underlie prostate cancer progression
por: Lin, Chun-Jung, et al.
Publicado: (2019)

Bacterial Genotoxin-Coated Nanoparticles for Radiotherapy Sensitization in Prostate Cancer
por: Chen, Yu-An, et al.
Publicado: (2021)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting
por: Sawant, Mithila, et al.
Publicado: (2022)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Gli2 mediates the development of castration-resistant prostate cancer
por: Xia, Lu, et al.
Publicado: (2020)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
por: Huang, Phoebe A., et al.
Publicado: (2018)

Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair
por: Chen, Yu-An, et al.
Publicado: (2018)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_idr11c4bithotsnkaribi601ec